102O Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1–positive locally advanced/metastatic NSCLC.

Authors :: Mok, T S K
Wu, Y-L
Kudaba, I
Kowalski, D M
Cho, B C
Turna, H Z
Castro, G de
Srimuninnimit, V
Laktionov, K K
Bondarenko, I
Kubota, K
Caglevic, C
Karaszewska, B
Dang, T
Yin, L
Penrod, J
Lopes, G
Source :: Annals of Oncology. 2019 Supplement, Vol. 30, pN.PAG-N.PAG. 1p. 1 Chart.
Publication Year :: 2019

Subjects :: *PEMBROLIZUMAB
*NON-small-cell lung carcinoma
*CANCER chemotherapy
*MEDICAL sciences

Full Text Access

Tools